Overview

• A study published in JAMA Ophthalmology examined nine cases of serious eye complications in patients using semaglutide and tirzepatide, drugs commonly prescribed for type 2 diabetes and obesity.
• Seven patients were diagnosed with nonarteritic anterior ischemic optic neuropathy (NAION), a condition involving sudden vision loss due to reduced blood flow to the optic nerve.
• Researchers hypothesize that rapid blood sugar improvements caused by these medications may contribute to optic nerve damage in some individuals, though causation has not been established.
• The study's authors emphasize the need for further research to confirm any potential links and recommend that patients experiencing sudden vision changes seek immediate medical attention.
• Semaglutide and tirzepatide are widely used, with nearly 2% of Americans prescribed semaglutide in 2023, underscoring the importance of monitoring potential side effects as usage grows.